On September 14, 2020, the Company announced that it plans to report top-line final data for the dose optimization part of the open-label dose optimization and schedule optimization Phase 1b portion of its Phase 1b/2 clinical trial of ALRN-6924 in patients with small cell lung cancer (“SCLC”) at the 2020 EORTC-NCI-AACR conference. The Company continues to expect to report preliminary schedule optimization data in the fourth quarter of 2020.

The Company plans to initiate a clinical trial of ALRN-6924 in healthy volunteers to characterize the time to onset, the magnitude and the duration of cell cycle arrest in human bone marrow relative to ALRN-6924 administration in the fourth quarter of 2020.

Subject to the results of the healthy volunteer study and data from the dose- and schedule-optimization trials, and to obtaining sufficient funding, the Company expects to initiate Phase 1b/2 clinical trials in non-small cell lung cancer in the second half of 2021 and in a gastrointestinal cancer indication at an as yet undetermined time. The Company does not currently plan to conduct additional development of ALRN-6924 in patients with SCLC.

Forward-Looking Statements

Statements in this report and Exhibit 99.1 about Company’s future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about the Company’s strategy and clinical development plans. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether the Company’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial will be indicative of the final results of the trial; whether the Company’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether the Company’s product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; whether the coronavirus pandemic will have an impact on the timing of the Company’s clinical development, clinical supply and its operations; and other factors discussed in the “Risk Factors” section of the Company’s quarterly report on Form 10-Q for the period ended June 30, 2020, and risks described in other filings that the Company may make with the Securities and Exchange Commission. Any forward-looking statements contained in this report and Exhibit 99.1 speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.